C3i participates to the challenge Cycle for a cure!

I am text block. 

Saturday, September 30, 2017

The 6th edition of the Bike Challenge for Cellular Therapy Research at the Maisonneuve-Rosemont Hospital will give you the opportunity to support scientific work that promotes healing.

With you, we can make a difference!

This 6th edition is dedicated to the memory of Matthew Schreindorfer. Come and encourage her spouse Katia Luciani, spokesperson and honorary president of the event.

Challenge – Cycle for a cure!

On this occasion, the C3i team meets to pedal and raise funds for the HMR Foundation. François Bettez, our CEO and Dr Lambert Busque our CMO will ride their bike for the good cause.


For more details, to register or to make a donation, visit pedalonspourguerir.com

Saturday, September 30, 2017

At the Gilles-Villeneuve circuit



I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

IRICoR and C3i Announce Partnership to Identify novel Tumor-Specific Antigens (TSAs)

Novel Approach to Identifying TSAs based on a unique mass spectrometry approach discovered at IRIC combined with expertise in genomic sequencing and clinical validation from C3i

Montreal, April 4, 2017The Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) and the Centre for Commercialization of Cancer Immunotherapy (C3i) are pleased to announce a major collaboration to identify novel tumor specific antigens (TSAs) in a number of solid and hematological cancers. This collaboration will exploit a novel method to identify Major Histocompatibility Complex (MHC)-associated peptides by mass spectrometry developed by Dr. Claude Perreault and colleagues at the Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal. Under the leadership of Dr. Lambert Busque, a haematologist involved in clinical research and biomarkers development at Maisonneuve-Rosemont Hospital, C3i will be adding their expertise in genomic sequencing and clinical validation for the targeted indications. In addition to access to their mutual intellectual property and related know-how, IRICoR and C3i will jointly finance the project.

“We are very excited to initiate this first collaboration with C3i,” commented Dr. Nadine Beauger, Chief Executive Officer at IRICoR. “Our combined expertise will allow us to deliver clinically validated therapies from academic innovation initially identified and supported by IRICoR. With the support of IRICoR, Dr. Perreault and his colleagues are developing a novel and unique approach to rapidly identifying clinically relevant TSAs which can stimulate MHC Class I-specific T cell responses. By having access to human tumor samples as well as the cell therapy and clinical expertise at C3i, this collaboration will allow us to generate important proof of concept data and contribute to a significant scientific trend in cancer immunotherapy. This very promising collaboration is a further example of IRICoR’s strategic positioning at the centre of the drug discovery and project maturation chain in academia.”

“We are extremely delighted to be partnering with IRICoR in this project and leveraging their deep scientific knowledge. I look forward to a long and successful strategic collaboration” said Francois Bettez, Chief Executive Officer of C3i. ”The identification of tumor-specific neoantigens is vital for the development of targeted therapies that maximize antitumor efficacy and minimize off-target toxicities and is fully aligned with our mandate to support discovery, commercialisation and access to new cancer immunotherapies. This collaborative initiative is an extraordinary opportunity to bring together two acclaimed research teams to help find innovative solutions in this booming approach. The expertise of C3i and IRICoR are in continuum to accelerate access to innovative cancer immunotherapies for patients.” 

About C3i

The Centre for Commercialization of Cancer Immunotherapy (C3i) is a unique entity created in early 2016 with the ultimate goal to accelerate access to innovative cancer immunotherapies for Canadians. Our vision is to be Canada’s catalyst for cancer immunotherapy business development. C3i will be the only Canadian immunotherapy development organisation that will lead to the clinical implementation and to the commercialization of these new therapeutic methods. To this end, we propose a novel business model combining direct patient clinical diagnostics using new genomic technologies, good manufacturing practices (GMP) standards and rapid access to clinical trials and regulatory support.

About Maisonneuve Rosemont Hospital

Affiliated to the Université de Montréal, Hôpital Maisonneuve-Rosemont (HMR), part of CIUSSS-1954. The HMR has a major research center of close to sixty researchers. There are four distinct sectors at the national and international levels: immuno-oncology, vision health, nephrology and cell therapy. Each year, the HMR receives more than 4,000 students, future physicians, nurses and health care professionals

About the Institute for Research in Immunology and Cancer (IRIC)

An ultra-modern research hub and training centre located in the heart of the Université de Montreal, IRIC was created in 2003 to shed light on the mechanisms of cancer and discover new, more effective therapies to counter this disease. IRIC operates according to a model that is unique in Canada. Its innovative approach to research has already led to discoveries that will, over the coming years, have a significant impact on the fight against cancer. For more information: www.iric.ca.

About the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR)

As Université de Montréal’s drug discovery and project maturation cluster, IRICoR is a not-for-profit organization based at IRIC, with the mandate to accelerate the discovery, development and commercialization of novel therapies in cancer, immunotherapy and related fields. Since its creation in 2008, IRICoR successfully invests in and supports cutting-edge projects with disruptive technologies to rapidly translate innovation into patient-accessible therapies, through either co-development partnerships with industry or company creation. IRICoR seamlessly integrates business-related expertise with industry-level drug discovery in a world-renowned research institute, providing academics with access to a full drug discovery chain with one of the largest academia-based medicinal chemistry groups in Canada. For more information about IRICoR: www.iricor.ca



$29 million investment in two commercialization centres will accelerate Canadians’ access to innovative cancer immunotherapies and natural products



February 12, 2016 – Charlottetown, PEI — Networks of Centres of Excellence

Today, the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development, joined by the Honourable Lawrence MacAulay, Minister of Agriculture and Agri-food, and the Honourable Wade MacLauchlan, Premier of Prince Edward Island, announced two significant investments in research commercialization centres.

In Charlottetown, the Natural Products Canada (NPC) will receive $14 million over five years, in support of its work to establish Canada as a global leader in the development and marketing of natural products.

In Montréal, the Centre for Commercialization of Cancer Immunotherapy (C3i) will receive funding of $15 million over five years to develop, translate and commercialize cancer immunotherapy.

These two recipients are the two successful applicants from the most recent competition in the Centres of Excellence for Commercialization and Research (CECR) program. The CECRs match clusters of research expertise with the business community, facilitating the development of products and technologies at a stage in the commercialization process where it is otherwise difficult to attract private-sector investment.


“Today’s CECR recipients reflect the impressive depth and quality of research conducted here in Canada in two vital areas: innovative cancer therapies and ground-breaking natural alternatives to products already on the market. The Government of Canada is proud to support this important stage on the research spectrum: getting products out of the lab and into the market, so that they can begin to improve the lives of Canadians.”
– The Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development

“The CECR program helps to fill that important gap between conducting research, and being able to develop a commercially viable product. Today’s announcement is yet another example of the great scientific research that is being done across the country, and the tremendous efforts that these researchers are making to dream beyond their research, and to how they can improve our quality of life. Congratulations to both successful organizations.”
– The Honourable Kirsty Duncan, Minister of Science

“Our research ecosystem needs to be balanced in a way that supports the constant interchange between discovery and innovation. Commercialization centres satisfy a very specific need, by providing a solid connection between the ideas generated by foundational research and the expertise that can take the most promising ideas towards commercialization.”
– B. Mario Pinto, President, Natural Sciences and Engineering Research Council, and Chair, Networks of Centres of Excellence Steering Committee

“By harnessing the power of the immune system, we have the potential to revolutionize cancer treatment. These are game-changing therapies, and with this support C3i can work to ensure a brighter future for cancer patients. At the same time, Canada has the expertise in this area to become a world leader and take advantage of the tremendous business opportunity presented by immunotherapy. C3i will act as a catalyst to support this development.”
–  Lambert Busque, Chief Medical Officer, C3i

“This funding will enable us to link Canada’s natural products assets, strengthen the sector’s position within the global market and realize positive outcomes for Canadians. Together with our founding partners, we can connect existing research, infrastructure and expertise from regions across Canada, and we are pleased to lead the first national CECR hosted in the Maritimes.”
–  Shelley R. King, Chief Executive Officer of Natural Products Canada

Quick facts

The NPC, headquartered in Charlottetown, will capitalize on ongoing research that has demonstrated a wealth of applications for natural products in promoting good human and animal health. They will also work to develop green alternatives to agricultural products and industrial chemicals. The centre will evaluate, scientifically validate and invest in products and technologies. C3i, which is based in Montréal, will accelerate access to innovative cancer immunotherapies for patients. Operating out of the Hôpital Maisonneuve-Rosemont’s Research Centre, C3i will be a one-stop shop for the development, translation and commercialization of ground-breaking cancer treatments. The CECR program currently funds 23 centres, working in areas that include information and communications technologies, health, natural resources and energy. Created in 2007, the program invests $30 million per year in Canadian innovation.

Associated links

CECR competition results
CECR program information
Currently funded CECRs 


Media Relations
Innovation, Science and Economic Development Canada

Martin Leroux
Media and Public Affairs Officer
Natural Sciences and Engineering Research Council

The Networks of Centres of Excellence, which manages the CECR program, operates a suite of national funding programs on behalf of the three federal granting agencies—the Natural Sciences and Engineering Research Council (NSERC), the Canadian Institutes of Health Research (CIHR), and the Social Sciences and Humanities Research Council (SSHRC). NCE programs support large scale, multi-disciplinary collaborations between universities, industry, government and not-for-profit organizations, which focus Canada’s research capacity on economic and social challenges, help commercialize and apply research breakthroughs, increase private-sector R&D, and train highly qualified people.